张学农教授课题组在Journal of Biomedical Materials Research Part B发表研究论文

发布者:系统管理员发布时间:2013-05-21浏览次数:1098

Novel albendazole-chitosannanoparticles for intestinal absorption enhancement and hepatic targetingimprovement in rats

Yang Liu, Xiao-qing Wang, Wei-xin Ren, Yuan-lan chen, Yang Yu, Jian-kang Zhang, Dilimulati·Bawudong, Jun-peng Gu, Xiao-dong Xu, Xue-nong Zhang
Journal of Biomedical Materials Research Part B(二区,IF=2.147)2013 Mar 26. doi: 10.1002/jbm.b.32908. [Epub ahead of print]
To improve the treatment of helminthiasis, filariasis, and colorectal cancer, albendazole-associated chitosan nanoparticles (ABZ-CS-NPs) were prepared using the emulsion crosslinking technique. Sodium tripolyphosphate and Poloxamer188 were used as the cross-linking agent and auxiliary solvent, respectively. The structural characteristics of the NPs were determined by X-ray diffraction toanalyze CS–albendazole interaction. Through animal studies, the NPs were evaluated in terms of their physicochemical characteristics, drug release behavior, in vivo pharmacokinetic parameters, and biodistribution. ABZ-loaded NPs with uniformly spherical particles (157.8 nm ± 2.82 nm) showed efficient drug loading, efficient encapsulation, and high physical stability. The drug release from ABZ-CS-NPs was extended over several periods. Kinetic models were then fitted to determine the release mechanisms. ABZ and its metabolite, albendazole sulphoxide (ABZSX), were analyzed by reversed-phase high-performance liquid chromatography. For the analysis, rats were used with mebendazole as the internal standard. Compared with therelative bioavailability values of ABZ suspension groups, those of ABZ and ABZSX were 146.05% and 222.15%, respectively. In addition, the plasma concentration versus time curve is consistent with that of the two compartment models. Results indicate that the ABZ-loaded NPs are promising ABZ candidates for passive diffusion in the oral treatment of hydatid cysts in the liver.

zxnktz01.JPG